Peptides
KLOW
80mg
Pre-blended four-peptide research vial. KPV 10mg + BPC-157 10mg + TB-500 10mg + GHK-Cu 50mg.
>99% purity · Third-party tested · Batch UKPL-609 · View certificate
- Same-day dispatch before 3pm, Mon to Fri
- Qualifies for free UK delivery
- Cold-chain shipping. Always. Dry-cold pack, Royal Mail Tracked 24
- Lost, damaged or wrong? Replaced free if you tell us within 48 hours.
- Research use only. For in-vitro laboratory research. Not for use in humans or animals, or in food, drugs or diagnostics. Not evaluated by the MHRA or FDA. The buyer is responsible for handling and regulatory compliance.
Bulk Pricing
Counted across your basket, any mix of products.
| Vials in basket | Discount | Per vial |
|---|---|---|
| 1 | None | £79.99 |
| 3-4 | 5% | £75.99 |
| 5-9 | 8% | £73.59 |
| 10-50 | 12% | £70.39 |
Bacteriostatic Water 10ml
Required to reconstitute lyophilised peptides.
What is KLOW?
KLOW is an 80mg blend of four peptides co-lyophilised in one vial. It takes one reconstitution, where some UK suppliers sell the same four compounds as a five- or six-vial kit.
Full description
KLOW is a supplier name for a blend, not a single compound. It is the GLOW trio of BPC-157, TB-500 and GHK-Cu with KPV added, which is where the K comes from. The four components dissolve together at a fixed ratio and cannot be separated afterwards. No published study has tested them as a combination, so the evidence base is four single-compound literatures.
KLOW Research Applications
- KPV 10mg: PepT1-mediated uptake and reduced NF-κB activation in human intestinal epithelial and T cell lines (Dalmasso et al., 2008).
- BPC-157 10mg: VEGFR2 up-regulation and VEGFR2-Akt-eNOS signalling in endothelial cells and a rat hind limb ischaemia model (Hsieh et al., 2017).
- TB-500 10mg: the seven amino acid actin-binding motif of thymosin beta-4 drove endothelial cell migration and vessel sprouting (Philp et al., 2003).
- GHK-Cu 50mg: raised MMP-2 expression and TIMP-1 and TIMP-2 secretion in dermal fibroblast cultures (Siméon et al., 2000).
Study details
Each result above comes from one component tested alone, in its own model system. KPV is the component that sets KLOW apart. KPV given in drinking water reduced DSS- and TNBS-induced colitis in mice (Dalmasso et al., Gastroenterology, 2008). Its effect on colitis-associated tumour formation was absent in PepT1-knockout mice (Viennois et al., Cell Mol Gastroenterol Hepatol, 2016). Kannengiesser et al. (Inflamm Bowel Dis, 2008) reported activity in two murine colitis models that was partly independent of MC1R.
KLOW also works as a convenience preparation when four compounds are wanted in one solution. Use the individual vials whenever a design needs a single-compound control.
KLOW vs GLOW
GLOW is a 70mg vial of BPC-157 10mg, TB-500 10mg and GHK-Cu 50mg. KLOW is 80mg: the same three at the same masses plus KPV 10mg. The difference is mechanism, not quantity. BPC-157, TB-500 and GHK-Cu are studied for angiogenic signalling, actin binding and cell migration, and copper-dependent matrix remodelling. KPV acts through a transporter. It enters gut epithelial and immune cells via PepT1, a di- and tripeptide transporter induced in the colon during inflammation.
Research Overview
KPV is alpha-MSH(11-13), the C-terminal tripeptide Lys-Pro-Val. Its mechanism does not run through the melanocortin receptors. Mandrika et al. (Biochem Pharmacol, 2001, PMID 11239505) found that it did not bind MC1 receptor sites or raise cAMP in RAW 264.7 macrophage-like cells. It still inhibited NF-κB translocation and nitric oxide production. Its selectivity comes from the PepT1 transporter, which is expressed in the small intestine and induced in the colon during inflammation (Dalmasso et al., Gastroenterology, 2008, PMID 18061177). Viennois et al. (Cell Mol Gastroenterol Hepatol, 2016, PMID 27458604) made the transporter the gating step: KPV had no effect on tumour formation in PepT1-knockout mice.
One literature trap applies. The dimer (CKPV)₂ is a different molecule with its own investigational record, and its results do not transfer to KPV. The BPC-157, TB-500 and GHK-Cu literatures are covered on the GLOW and single-compound pages.
Product Specifications
- Format
- Pre-blended single vial, four components co-lyophilised
- Components
- KPV 10mg + BPC-157 10mg + TB-500 10mg + GHK-Cu 50mg
- Total Mass
- 80mg per vial
- KPV Component
- 10mg, Lys-Pro-Val, alpha-MSH(11-13), 342.4 g/mol, CAS 67727-97-3
- BPC-157 Component
- 10mg, pentadecapeptide GEPPPGKPADDAGLV, C₆₂H₉₈N₁₆O₂₂, 1419.53 g/mol, CAS 137525-51-0
- TB-500 Component
- 10mg, thymosin beta 4, 43 residues, C₂₁₂H₃₅₀N₅₆O₇₈S, 4963.4 g/mol, CAS 77591-33-4
- GHK-Cu Component
- 50mg, glycyl-L-histidyl-L-lysine copper(II) complex, C₁₄H₂₄CuN₆O₄, 403.9 g/mol, CAS 89030-95-5
- Purity
- Each component ≥98%
- Batch
- UKPL-609
- Certificate of Analysis
- Chromatographic purity >99% by RP-HPLC (UV 214 nm) against a 98.0% specification; Marfleet Analytical Services, analysis 07/08/2026, report 28/08/2026
- Storage
- -20°C lyophilised, 2-8°C reconstituted, protect from light
- Appearance
- Blue lyophilised powder (Cu(II) from GHK-Cu)
- Form
- Lyophilised powder (single vial)
Certificate of Analysis
Third-party tested
- Batch
- UKPL-609
- Purity
- >99%
- Method
- HPLC-UV
- Lab
- Marfleet Analytical Services
- Tested
- Aug 2026
Need the certificate for an earlier batch? Request an older CoA
Storage and Reconstitution
Store the sealed KLOW vial at -20°C, away from light. GHK-Cu is a light-sensitive copper(II) complex, so handle the whole blend to that standard and use amber or foil-wrapped vessels for aliquots. Keep reconstituted solution refrigerated at 2-8°C. Freeze-thaw cycles degrade the peptide chains and can disrupt the copper complex, so freeze single-use aliquots instead of re-opening one stock.
Vials are sold on their own, without bacteriostatic water for mixing or other supplies.
How to reconstitute and handle
Let the vial reach room temperature before opening so condensation does not settle on the cake. Run bacteriostatic water slowly down the inside wall of the vial and swirl gently until dissolved. Do not shake or vortex, because the thymosin beta-4 component is shear-sensitive. Expect a blue to blue-violet solution from the Cu(II) centre of GHK-Cu. A colourless or green-tinged solution suggests the copper complex has been disrupted. Label the vial with the reconstitution date.
- Use glass or high-grade polypropylene labware. Stainless steel, strong chelators, phosphate-rich buffers and reducing agents can strip or compete for the copper in GHK-Cu.
- Absorbance in the 500 to 600 nm region is the standard bench check that the copper complex is intact.
- KPV, at 342.4 g/mol, is the component most easily lost to surface adsorption and to filtration or dialysis steps with a molecular weight cut-off.
- Swab both stoppers with 70% isopropyl alcohol before every needle entry and use a fresh sterile syringe for each transfer.
For the full method, see the peptide reconstitution guide and the reconstitution calculator.
Research References
- PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation (Dalmasso et al., Gastroenterology, 2008)
- Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the PepT1-mediated tripeptide KPV in a murine model (Viennois et al., Cell Mol Gastroenterol Hepatol, 2016)
- Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease (Kannengiesser et al., Inflamm Bowel Dis, 2008)
- Effects of melanocortin peptides on NF-kappaB DNA binding and nitric oxide production in RAW 264.7 cells, evidence for dual mechanisms of action (Mandrika et al., Biochem Pharmacol, 2001)
- Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation (Hsieh et al., J Mol Med, 2017)
- The actin binding site on thymosin beta4 promotes angiogenesis (Philp et al., FASEB J, 2003)
- The tripeptide-copper complex GHK-Cu stimulates matrix metalloproteinase-2 expression by fibroblast cultures (Siméon et al., Life Sci, 2000)
Published research on KLOW is indexed on PubMed. See our full UK buyer's guide for KLOW.
KLOW Price (UK)
KLOW 80mg is for sale at £79.99 per vial, supplied from stock in the UK with a published third-party HPLC certificate. UK delivery by Royal Mail Tracked 24 is free at this price.
| Vial | Price | Cost per mg | Availability |
|---|---|---|---|
| KLOW 80mgThis page | £79.99 | £1.00 | In stock |
Prices are in GBP per vial and match the basket. See the FAQ for delivery and payment options, and quality & testing for how each batch is checked.
Frequently Asked Questions
What is the difference between KLOW and GLOW?
KLOW is GLOW plus KPV 10mg. GLOW is a 70mg vial of BPC-157 10mg, TB-500 10mg and GHK-Cu 50mg. KLOW is 80mg, with the same three at the same masses plus KPV. The KPV literature centres on PepT1 uptake and NF-κB signalling in gut epithelial and colitis models.
What is in a KLOW 80mg vial?
Each vial holds 80mg of co-lyophilised powder: KPV 10mg, BPC-157 10mg, TB-500 10mg and GHK-Cu 50mg. The current batch is UKPL-609. Its certificate reports >99% chromatographic purity by RP-HPLC and a blue powder, the colour coming from the copper in GHK-Cu.
What is KPV and what is it studied for?
KPV is the tripeptide Lys-Pro-Val, 342.4 g/mol, residues 11 to 13 of alpha-MSH. It is studied in intestinal inflammation models. Dalmasso et al. (Gastroenterology, 2008, PMID 18061177) reported uptake through the PepT1 transporter and reduced NF-κB activation in human epithelial and immune cell lines. Kannengiesser et al. (2008) reported activity in murine colitis that was partly independent of MC1R.
Has KPV been tested in humans?
No. There are no human trials of KPV itself. The published record is cell culture work, including human cell lines, and rodent models. (CKPV)₂, a dimer of two KPV units joined by a cysteine linker, has its own investigational history, and its results do not transfer to the bare tripeptide.
Has the KLOW blend been studied as a combination?
No. No published study has examined KPV, BPC-157, TB-500 and GHK-Cu together, at this ratio or any other, and no combined effect has been shown. Every cited finding comes from one component tested alone. Plan controls on that basis, with individual vials wherever an effect must be attributed to one compound.
Are KLOW peptides supplied as one pre-blended vial or as a multi-vial kit?
One pre-blended vial. Some suppliers sell KLOW as five or six separate vials that the researcher combines. Here all four components are co-lyophilised, so there is one reconstitution and one vial to label and store. A kit keeps one advantage: independent control of each component's concentration.
Where can I buy KLOW peptide UK?
UK Peptide Lab sells KLOW 80mg online as a single pre-blended research vial, dispatched from the UK. The current batch, UKPL-609, has its third-party certificate published with the listing. Orders placed before 3pm on a working day are dispatched the same day, and UK delivery is free over £69.
What purity are your KLOW peptides, and is there a per-component certificate of analysis?
Batch UKPL-609 tested at >99% chromatographic purity by RP-HPLC against a ≥98.0% specification. The third-party certificate gives one purity figure for the whole blend, not a separate result for each component. The sample was analysed on 7 August 2026, and the full certificate is published in the certificate section so you can check it before ordering.
Is KLOW legal to buy in the UK for research?
Yes, for in-vitro laboratory research. KLOW is not a licensed medicine and is not approved for human or veterinary use, cosmetic use or any therapeutic purpose. Buyers must be 18 or over and confirm research-only use at checkout.
Should I choose KLOW or GLOW for my research model?
Choose KLOW if your model includes epithelial barrier, mucosal inflammation or colitis biology, because that is where the KPV literature sits. If it does not, the extra 10mg of KPV adds cost without a relevant mechanism, and GLOW is the closer fit. Use individual vials when you need a single-compound control arm.
Related Products
